Citations (20)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (4)
Hugh Young Rienhoff$suffix/text()$suffix/text() & Harinder Gill. (2023) Bomedemstat as an investigative treatment for myeloproliferative neoplasms. Expert Opinion on Investigational Drugs 32:10, pages 879-886.
Read now
Read now
Anita Sarma, Donal P Mclornan & Claire N Harrison. (2017) Spotlight on anagrelide hydrochloride for the treatment of essential thrombocythemia. Orphan Drugs: Research and Reviews 7, pages 11-23.
Read now
Read now
Matjaz Sever, Kate J. Newberry & Srdan Verstovsek. (2014) Therapeutic options for patients with polycythemia vera and essential thrombocythemia refractory/resistant to hydroxyurea. Leukemia & Lymphoma 55:12, pages 2685-2690.
Read now
Read now
Gunnar Birgegård. (2013) Pharmacological management of essential thrombocythemia. Expert Opinion on Pharmacotherapy 14:10, pages 1295-1306.
Read now
Read now
Articles from other publishers (16)
Adam Kellner, Peter Dombi, Arpad Illes, Judit Demeter, Lajos Homor, Ibolya Ercsei, Zsofia Simon, Eva Karadi, Jozsef Herczeg, Viktoria Gy Korom, Zoltan Gasztonyi, Laszlo Szerafin, Miklos Udvardy & Miklos Egyed. (2020) Anagrelide influences thrombotic risk, and prolongs progression‐free and overall survival in essential thrombocythaemia vs hydroxyurea plus aspirin. European Journal of Haematology 105:4, pages 408-418.
Crossref
Crossref
Hans Michael Kvasnicka. 2020. Hematopathology. Hematopathology
142
146
.
Barbara J. Bain, David M. Clark & Bridget S. Wilkins. 2019. Bone Marrow Pathology. Bone Marrow Pathology
267
345
.
Hans Michael Kvasnicka. 2019. Encyclopedia of Pathology. Encyclopedia of Pathology
1
5
.
Tiziano Barbui, Jürgen Thiele, Heinz Gisslinger, Hans Michael Kvasnicka, Alessandro M. Vannucchi, Paola Guglielmelli, Attilio Orazi & Ayalew Tefferi. (2018) The 2016 WHO classification and diagnostic criteria for myeloproliferative neoplasms: document summary and in-depth discussion. Blood Cancer Journal 8:2.
Crossref
Crossref
Georg Jeryczynski, Jürgen Thiele, Bettina Gisslinger, Albert Wölfler, Martin Schalling, Andreas Gleiß, Sonja Burgstaller, Veronika Buxhofer-Ausch, Thamer Sliwa, Ernst Schlögl, Klaus Geissler, Maria-Theresa Krauth, Alexander Nader, Michael Vesely, Ingrid Simonitsch-Klupp, Leonhard Müllauer, Christine Beham-Schmid & Heinz Gisslinger. (2017) Pre-fibrotic/early primary myelofibrosis vs. WHO-defined essential thrombocythemia: The impact of minor clinical diagnostic criteria on the outcome of the disease. American Journal of Hematology 92:9, pages 885-891.
Crossref
Crossref
T. Barbui, J. Thiele, H. Gisslinger, G. Finazzi, A.M. Vannucchi & A. Tefferi. (2016) The 2016 revision of WHO classification of myeloproliferative neoplasms: Clinical and molecular advances. Blood Reviews 30:6, pages 453-459.
Crossref
Crossref
Gunnar Birgegård. (2016) The Use of Anagrelide in Myeloproliferative Neoplasms, with Focus on Essential Thrombocythemia. Current Hematologic Malignancy Reports 11:5, pages 348-355.
Crossref
Crossref
Tiziano Barbui, Jürgen Thiele, Alessandro M. Vannucchi & Ayalew Tefferi. (2016) Myeloproliferative neoplasms: Morphology and clinical practice. American Journal of Hematology 91:4, pages 430-433.
Crossref
Crossref
H Gisslinger, G Jeryczynski, B Gisslinger, A Wölfler, S Burgstaller, V Buxhofer-Ausch, M Schalling, M-T Krauth, A-I Schiefer, C Kornauth, I Simonitsch-Klupp, C Beham-Schmid, L Müllauer & J Thiele. (2015) Clinical impact of bone marrow morphology for the diagnosis of essential thrombocythemia: comparison between the BCSH and the WHO criteria. Leukemia 30:5, pages 1126-1132.
Crossref
Crossref
Hans Michael Kvasnicka. 2016. Managing Myeloproliferative Neoplasms. Managing Myeloproliferative Neoplasms
22
36
.
Ann B. Madelung, Henrik Bondo, Inger Stamp, Preben Løvgreen, Signe L. Nielsen, Anne Falensteen, Helle Knudsen, Kira D. Svendsen, Theis Lange, Elisabeth Ralfkiaer, Karsten Nielsen, Hans Hasselbalch & Jürgen Thiele. (2015) WHO classification 2008 of myeloproliferative neoplasms: a workshop learning effect - the Danish experience. APMIS 123:9, pages 787-792.
Crossref
Crossref
T Barbui, J Thiele, A M Vannucchi & A Tefferi. (2015) Rationale for revision and proposed changes of the WHO diagnostic criteria for polycythemia vera, essential thrombocythemia and primary myelofibrosis. Blood Cancer Journal 5:8, pages e337-e337.
Crossref
Crossref
Gunnar Birgegård. (2015) Advances and challenges in the management of essential thrombocythemia. Therapeutic Advances in Hematology 6:3, pages 142-156.
Crossref
Crossref
Hans Michael Kvasnicka. (2013) WHO Classification of Myeloproliferative Neoplasms (MPN): A Critical Update. Current Hematologic Malignancy Reports 8:4, pages 333-341.
Crossref
Crossref
T Barbui, J Thiele, A M Vannucchi & A Tefferi. (2013) Problems and pitfalls regarding WHO-defined diagnosis of early/prefibrotic primary myelofibrosis versus essential thrombocythemia. Leukemia 27:10, pages 1953-1958.
Crossref
Crossref